flomoxef

Flomoxef is a second-generation oxacephem antibiotic, structurally related to cephalosporins but with an oxygen atom in the dihydrothiazine ring instead of sulfur. It acts as a broad-spectrum, bactericidal β-lactam agent by binding to penicillin-binding proteins (PBPs) and inhibiting bacterial cell wall synthesis through prevention of peptidoglycan cross-linking. This mechanism leads to bacterial cell lysis and death. Flomoxef is notable for its activity against both Gram-positive and Gram-negative bacteria, including multidrug-resistant strains such as ESBL-producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus (MRSA). It is primarily used for severe systemic infections, postoperative prophylaxis, urinary tract infections, intra-abdominal infections, pelvic infections, and other susceptible bacterial diseases[1][3][6][7][8]. Developed in Japan in the 1980s by Shionogi Research Laboratories, it remains an important option where resistance limits other therapies.

Brand names

FlumarinEfmoxFMOX

Other names

flomoxef sodiumoxacephem 6315-Soxacephem6315-Soxacephem-6315-SFlomoxefo